Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Immune Checkpoint Inhibitors

Angiogenesis Inhibitors

Antineoplastic Agents, Immunological

Growth Inhibitors

Immune checkpoint inhibitors plus angiogenesis inhibitors group

Immune checkpoint inhibitors without angiogenesis inhibitors group

PD-(L)1-based therapy plus Bevacizumab or Anlotinib

Immune checkpoint inhibitors plus angiogenesis inhibitors

Immune checkpoint inhibitors without angiogenesis inhibitors

Jing Xue

Immune checkpoint inhibitors(ICIs) combined with angiogenesis inhibitors may is synergistic in elderly patients with advanced non-small cell lung cancer(NSCLC), however its true efficacy is still unclear. The investigators retrospectively compared clinical efficacy and safety of driver-negative elderly patients with advanced NSCLC treated with ICIs with(or without)angiogenesis inhibitors in the Cancer Center of the Affiliated Suzhou Hospital of Nanjing Medical University.

The investigators reviewed the medical records of all lung cancer patients in the Cancer Diagnosis and Treatment Center of Suzhou Hospital Affiliated to Nanjing Medical University from January 1, 2019 to December 31, 2021, and a total of 79 patients were enrolled. The subjects were divided into two groups: the group treated with immune checkpoint inhibitors plus antiangiogenic drugs(IA group) and the group treated with immune checkpoint inhibitors without antiangiogenic drugs(NIA group). The data of PFS, OS, ORR, covariates, and Immune-related adverse events (irAEs) were collected through electronic medical records and follow-up. The primary endpoint of the study was PFS, and the secondary endpoints were OS, ORR and irAEs.All enrolled patients were followed up until August 1, 2022.

Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly Patients

Efficacy and Safety Analysis of Immune Checkpoint Inhibitors Plus Angiogenesis Inhibitors for Treatment of Advanced Driver-negative NSCLC in Elderly Patients：A Retrospective Study

PFS was defined as the time from the start of the first immunotherapy until disease progression or death

OS was defined as the time from the start of the first immunotherapy to death from any cause

ORR refers to the sum of complete response and partial response to treatment

Immune-related adverse events were evaluated according to the CTCAE5.0 criteria

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly Patients	NCT05688046	NSCLC	Immune checkpoi... Immune checkpoi...	65 Years -	Suzhou Municipal Hospital
Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly Patients	NCT05688046	NSCLC	Immune checkpoi... Immune checkpoi...	65 Years -	Suzhou Municipal Hospital

Spots Global Cancer Trial Database for immune checkpoint inhibitors plus angiogenesis inhibitors